Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 2/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22837638 | 0.99 | KDM1A (0.32) | KDM1A | |
| SCHEMBL22861754 | 0.88 | KDM1A (0.32) | KDM1A | |
| SCHEMBL23602775 | 0.87 | PRMT6 (0.35) | KDM1AHTR7HTR1A | |
| SCHEMBL26465571 | 0.86 | KDM1A (0.31) | KDM1A | |
| SCHEMBL25109942 | 0.86 | KDM1A (0.31) | KDM1A | |
| SCHEMBL23696344 | 0.86 | PRMT6 (0.35) | KDM1AHTR7HTR1A | |
| SCHEMBL21107910 | 0.86 | PRMT6 (0.35) | KDM1AHTR7HTR1A | |
| SCHEMBL23806558 | 0.86 | GNAI3 (0.33) | KDM1AHTR7HTR1A | |
| SCHEMBL22861752 | 0.86 | KDM1A (0.32) | KDM1AHTR7HTR1A | |
| SCHEMBL23806789 | 0.85 | HTT (0.33) | KDM1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | KDM1A 822/4885HTR7 2787/4885HTR1A 3429/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | KDM1A 1488/4885HTR7 2560/4885HTR1A 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.